- Senior Investigator, Cancer and Inflammation Program
Dr. Oppenheim obtained his M.D. degree from the Columbia College of Physicians and Surgeons, New York, trained as a clinical associate at the National Cancer Institute (NCI), Bethesda, Maryland, and was a postdoctoral fellow at the University of Birmingham, England, in immunology. He returned to the National Institute of Dental Research and subsequently headed the Section of Cellular Immunology there and, since 1983, has been head of the Laboratory of Molecular Immunoregulation, NCI-Frederick.
- (2017). Alarmins and immunity. IMMUNOLOGICAL REVIEWS. 280(1), 41-56.
- (2017). Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. Scientific Reports. 7,
- (2017). Shock Synthesis of Decagonal Quasicrystals. Scientific Reports. 7,
- (2017). Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Science Signaling. 10(462),
- (2017). Therapeutic vaccine to cure large mouse hepatocellular carcinomas. 8(32), 52061-52071.